-
Ten recommendations to unlock the potential of big data for public health in the EU
Ten recommendations to unlock the potential of big data for public health in the EU
-
Ten recommendations to unlock the potential of big data for public health in the EU
Ten recommendations to unlock the potential of big data for public health in the EU
The HMA-EMA Joint Big Data task force proposes ten priority actions for the European medicines regulatory network to make best use of big data to support innovation and public health.
-
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13 – 16 January 2020
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13 – 16 January 2020
-
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13 – 16 January 2020
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13 – 16 January 2020
At its first monthly meeting in 2020, the PRAC recommended the suspension of Picato as a precaution, while it continues its review of the medicine’s safety. The Committee also confirmed a four-week limit for use of high-strength Estradiol creams.
-
Veterinary medicines: highlights of 2019
Veterinary medicines: highlights of 2019
-
Veterinary medicines: highlights of 2019
Veterinary medicines: highlights of 2019
EMA recommended marketing authorisations for 15 medicines for veterinary use in 2019.
-
Human medicines: highlights of 2019
Human medicines: highlights of 2019
-
Human medicines: highlights of 2019
Human medicines: highlights of 2019
EMA recommended marketing authorisations for 66 medicines for human use in 2019.
